Evidence map›Paper›PMID 25505168›Full record

ReviewPharmacological reviews2015

Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder.

Leonard L Howell, Kathryn A Cunningham

Open access · bronzeAbstract readReview
In one paragraph

Review in Pharmacological reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 146 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
146citing papers in PubMed, 1 pooled it
8.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

146 citing papers in PubMed, 1 synthesis or guideline pooled it, 255 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Biased Allosteric Modulation in GPCR Drug Discovery.Handbook of experimental pharmacology · 2026
    Review
  12. Article
  13. Article
  14. 5-HTMolecular psychiatry · 2025
    Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. 5-HTPharmacological reviews · 2025
    Review
  20. Applications of artificial intelligence in drug discovery for neurological diseases.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review

86 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Leonard L HowellYerkes National Primate Research Center, Emory University, Atlanta, Georgia (L.L.H.); and Center for Addiction Research and Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas (K.A.C.) lhowell@emory.edu.
Kathryn A CunninghamYerkes National Primate Research Center, Emory University, Atlanta, Georgia (L.L.H.); and Center for Addiction Research and Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas (K.A.C.).
The University of Texas Medical Branch at Galveston · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Translational Addiction Sciences CenterP50DA033935 · NIDA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI CUNNINGHAM, KATHRYN A. · 2013 to 2017
$6.7M
PET Imaging and Cocaine Neuropharmacology in MonkeysR37DA010344 · NIDA · EMORY UNIVERSITY · PI HOWELL, LEONARD L · 2007 to 2015
$4.9M
Addiction and the Neuropharmacology of PsychostimulantsK05DA020087 · NIDA · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI CUNNINGHAM, KATHRYN A. · 2005 to 2015
$1.3M
Neuropharmacology of Abused Stimulants in Nonhuman PrimatesK05DA031246 · NIDA · EMORY UNIVERSITY · PI HOWELL, LEONARD L · 2012 to 2016
$619k
NIDA NIH HHS K05 DA020087NIDA NIH HHS K05-DA020087NIDA NIH HHS K05 DA031246NIDA NIH HHS K05-DA031246NIDA NIH HHS P50 DA033935NIDA NIH HHS R37 DA010344NIH HHS P51 OD011132NIH HHS P51-OD11132
6 · The paper itself

Abstract

Cocaine exhibits prominent abuse liability, and chronic abuse can result in cocaine use disorder with significant morbidity. Major advances have been made in delineating neurobiological mechanisms of cocaine abuse; however, effective medications to treat cocaine use disorder remain to be discovered. The present review will focus on the role of serotonin (5-HT; 5-hydroxytryptamine) neurotransmission in the neuropharmacology of cocaine and related abused stimulants. Extensive research suggests that the primary contribution of 5-HT to cocaine addiction is a consequence of interactions with dopamine (DA) neurotransmission. The literature on the neurobiological and behavioral effects of cocaine is well developed, so the focus of the review will be on cocaine with inferences made about other monoamine uptake inhibitors and releasers based on mechanistic considerations. 5-HT receptors are widely expressed throughout the brain, and several different 5-HT receptor subtypes have been implicated in mediating the effects of endogenous 5-HT on DA. However, the 5-HT2A and 5-HT2C receptors in particular have been implicated as likely candidates for mediating the influence of 5-HT in cocaine abuse as well as to traits (e.g., impulsivity) that contribute to the development of cocaine use disorder and relapse in humans. Lastly, new approaches are proposed to guide targeted development of serotonergic ligands for the treatment of cocaine use disorder.

Indexed as

AnimalsBehavior, AddictiveBehavior, AnimalBrainCentral Nervous System StimulantsCocaineCocaine-Related DisordersDisease Models, AnimalDopamineDrug DesignHumansMolecular Targeted TherapyReceptor, Serotonin, 5-HT2AReceptor, Serotonin, 5-HT2CSerotonin AgentsSynaptic TransmissionCentral Nervous System StimulantsCocaineDopamineReceptor, Serotonin, 5-HT2AReceptor, Serotonin, 5-HT2CSerotonin Agents

Identifiers

PMID25505168
PMCPMC4279075
OpenAlexW2060324739

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.